Mar 6, 2026Physical Activity

Resistance Training Beats WB-EMS for Metabolic Syndrome

A head-to-head RCT found resistance training improved metabolic syndrome and preserved muscle during dieting, while WB-EMS did not beat control.

wb-emsresistance trainingmetabolic syndromemuscle mass

Read article →

Mar 6, 2026Nutrition

Two Opposite Diet Trials Found the Same Gut Microbe Signal

A 2025 avocado trial and a small ultra-processed-food trial both increased Faecalibacterium in obesity. Why that matters, and why it may not help health yet.

gut microbiomefaecalibacteriumavocadoultra-processed foods

Read article →

Mar 1, 2026Hormones

GLP-1 Drugs and Heart Failure: Benefit Seems to Depend on Obesity

GLP-1 drugs cut cardiovascular death broadly, but heart failure hospitalization benefit appears limited to obese patients. Here's what the evidence shows.

glp-1semaglutidetirzepatidehfpef

Read article →

Mar 1, 2026Cardiovascular Health

GLP-1s Cut Heart Failure Risk Only in Obesity

GLP-1 drugs lower cardiovascular death broadly, but heart failure hospitalization benefit appears limited to obesity-driven disease.

glp-1heart failureobesityhfpef

Read article →

Mar 1, 2026Longevity Research

Semaglutide’s COVID Signal in SELECT Needs Scrutiny

SELECT found semaglutide cut COVID-19 deaths without lowering infection rates. The result is intriguing, but it came from a secondary analysis with major caveats.

semaglutideglp-1covid-19mortality reduction

Read article →

Feb 28, 2026Cardiovascular Health

GLP-1 Drugs in Obese Heart Failure: Where the Benefit Is

A 2025 meta-analysis suggests GLP-1 drugs help some obese heart failure patients, but the signal looks strongest in HFpEF, not HFrEF.

semaglutideglp-1 agonistsheart failurehfpef

Read article →

Feb 28, 2026Glp1 Agonists

SELECT’s Undercovered Result: Fewer Hospitalizations on Semaglutide

SELECT made headlines for fewer heart attacks and strokes. The quieter result: semaglutide also cut hospital admissions and hospital days in high-risk obesity.

semaglutideglp-1 agonistweight losscardiovascular protection

Read article →

Feb 28, 2026Metabolic Health

Semaglutide Protects Kidneys and Reverses Prediabetes in SELECT Trial

SELECT secondary analyses: semaglutide cut kidney risk 22%, diabetes progression 78% in non-diabetic obese adults. Real signal, real caveats — full breakdown.

semaglutideglp-1 agonistdiabetes preventionkidney function

Read article →

Feb 28, 2026Cardiovascular Health

GLP-1 Drugs in Heart Failure: Real Promise, Tight Limits

Meta-analyses suggest GLP-1 drugs help obese patients with HFpEF feel and function better, but no trial has shown longer survival or clear benefit in HFrEF.

glp-1 agonistsheart failuresemaglutidehfpef

Read article →

← PreviousPage 2 of 2